ABOS News and Press, Acumen Pharmaceuticals Inc. From 05/11/22

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 11, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company wil...

The following slide deck was published by Acumen Pharmaceuticals, Inc. in conjunction with this event. For further details see: Acumen Pharmaceuticals (ABOS) Investor Presentation - Slideshow

CHARLOTTESVILLE, Va. and CARMEL, Ind., April 27, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that Frontie...

Image source: The Motley Fool. Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q4 2021 Earnings Call Mar 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Tran...

The following slide deck was published by Acumen Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Acumen Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Conference Call March 28, 2022 4:30 AM ET Company Participants John Woolford - IR, Westwicke Daniel O'Connell - President & CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participan...

Acumen Pharmaceuticals press release (NASDAQ:ABOS): FY GAAP EPS of -$5.02 misses by $1.56. FY Cash and cash  equivalents of $122.16M For further details see: Acumen Pharmaceuticals GAAP EPS of -$5.02 misses by $1.56

Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical testing Currently enrolling INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-as...

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company w...

Acumen Pharmaceuticals (NASDAQ:ABOS): Q3 GAAP EPS of -$0.10 beats by $0.07. Cash equivalents and marketable securities of $199.96M Press Release For further details see: Acumen Pharmaceuticals EPS beats by $0.07